Regulus Therapeutics Inc (NASDAQ:RGLS) has a beta value of 1.58 and has seen 2.8 million shares traded in the recent trading session. The company, currently valued at $60.25M, closed the recent trade at $0.92 per share which meant it lost -$0.25 on the day or -21.38% during that session. The RGLS stock price is -311.96% off its 52-week high price of $3.79 and -22.83% below the 52-week low of $1.13. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.34 million shares traded. The 3-month trading volume is 341.75K shares.
The consensus among analysts is that Regulus Therapeutics Inc (RGLS) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.23.
Regulus Therapeutics Inc (NASDAQ:RGLS) trade information
Sporting -21.38% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the RGLS stock price touched $0.92 or saw a rise of 28.68%. Year-to-date, Regulus Therapeutics Inc shares have moved -41.78%, while the 5-day performance has seen it change -25.82%. Over the past 30 days, the shares of Regulus Therapeutics Inc (NASDAQ:RGLS) have changed -42.51%. Short interest in the company has seen 1.76 million shares shorted with days to cover at 5.51.
Regulus Therapeutics Inc (RGLS) estimates and forecasts
Figures show that Regulus Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -49.74% over the past 6 months, with this year growth rate of 44.30%, compared to 17.30% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 50.96% over the past 5 years. Earnings growth for 2025 is a modest 46.05% while over the next 5 years, the company’s earnings are expected to decrease by -0.36%.
RGLS Dividends
Regulus Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Regulus Therapeutics Inc (NASDAQ:RGLS)’s Major holders
Insiders own 2.34% of the company shares, while shares held by institutions stand at 88.31% with a share float percentage of 90.42%. Investors are also buoyed by the number of investors in a company, with Regulus Therapeutics Inc having a total of 96.0 institutions that hold shares in the company. The top two institutional holders are FEDERATED HERMES, INC. with over 12.85 million shares worth more than $22.94 million. As of 2024-06-30, FEDERATED HERMES, INC. held 19.9374% of shares outstanding.
The other major institutional holder is RA CAPITAL MANAGEMENT, L.P., with the holding of over 6.25 million shares as of 2024-06-30. The firm’s total holdings are worth over $11.16 million and represent 9.6952% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Federated Hermes Kaufmann Fund and Vanguard Total Stock Market Index Fund. As of Oct 31, 2024, the former fund manager holds about 12.03% shares in the company for having 7.88 shares of worth $7.25 million while later fund manager owns 2.5 shares of worth $2.3 million as of Sep 30, 2024, which makes it owner of about 3.82% of company’s outstanding stock.
